June 2017
Volume 3, Issue 7
This issue features a look at NIH’s new data-sharing requirements, Mikkael Sekeres’ thoughts on contract research organizations, and more.
Table of Contents
June 2017 Issue
Impatient Practicum
In his April 2017 Editor’s Corner, Editor-in-Chief Mikkael Sekeres issued his annual missive to the American Board of Internal Medicine (“Letter from a Cleveland...
Contract Research Agonizations
After years spent as an investigator on countless hematology and cancer clinical trials, all initiated with the noble intent of improving my patients’ lives...
Treating an older patient with CML and a sudden ANC drop?
Here’s how readers responded to a You Make the Call question about treating an older patient with chronic myeloid leukemia and a sudden ANC...
June 2017 Issue
ASH 2017 Bridge Grant Awards, Hematologists Receive Stand Up To Cancer 2017 Innovative Research...
ASH Announces 2017 Bridge Awards
The American Society of Hematology (ASH) announced the names of five investigators who have received the latest round of ASH...
Marching for Science, New Opportunities for International Collaboration, and more
Marching for Science
The first March for Science, which took place Saturday, April 22, 2017, in more than 600 locations around the world, drew hundreds...
June 2017 Issue
Show Me the Money? Show Us the Data!
How will NIH’s new requirement that federally funded clinical trials report outcomes affect researchers?
The merits and cautions of data sharing have long been a...
Uncommon Presentations, Uncommon Cancers
In this column, Beth Faiman, CNP, PhD, reviews the 5th edition of the Textbook of Uncommon Cancer.
Have you read any hematology-related books recently? Let...
Pulling Back the Curtain: Eduardo M. Sotomayor, MD
Where did you grow up?
I was blessed to grow up in a small, oceanside town (San Juan de Marcona) in the southern part...
June 2017 Issue
How to treat an older patient with CML and a sudden ANC drop?
This month, Michael W. Deininger, MD, PhD, discusses myelosuppression in a patient with chronic myeloid leukemia.
And don't forget to check out next month's clinical...
June 2017 Issue
Long-Term Follow-Up Confirms Safety, Efficacy of Imatinib for CML
Early results (published in Leukemia in 2009) from the phase III International Randomized Study of Interferon and STI571 (IRIS) demonstrated that imatinib 400 mg...
Predicting Response and Prognosis With Midostaurin in Advanced Systemic Mastocytosis
In April 2017, the U.S. Food and Drug Administration approved the multitargeted KIT inhibitor for the treatment of adult patients with FLT3-positive, newly diagnosed...
Pembrolizumab Prompts Response in Patients With Richter’s Transformation
Patients with chronic lymphocytic leukemia (CLL) who progress early during ibrutinib treatment often develop Richter’s transformation (RT), which is associated with an average survival...
Predicting Survival Outcomes for Children With Down Syndrome and AML or MDS
Children with Down syndrome (DS) have a higher risk of developing acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) than those without DS....
Deep Response With Venetoclax Plus Rituximab in Relapsed/Refractory CLL
Combining the selective BCL2 inhibitor venetoclax with rituximab may increase the depth and durability of response in patients with relapsed/refractory chronic lymphocytic leukemia (CLL),...
FDA Cautions Breast Augmentation May Be Linked to ALCL
The FDA is looking into 359 reports linking silicone and saline breast implants with development of anaplastic large cell lymphoma (ALCL), a rare type...
Manufacturers of KTE-C19 Report Patient Death
The manufacturer of the investigational chimeric antigen receptor (CAR) T-cell therapy KTE-C19 reported that one patient enrolled in the safety expansion phase of the...
FDA Grants Marketing Authorization for Genomic Sequencing Kit for PV
The U.S. Food and Drug Administration (FDA) granted marketing authorization to ipsogen JAK2 RGQ PCR Kit for the detection of JAK2 mutations. This is...
Ibrutinib Granted Supplemental New Drug Application for Chronic GVHD
The U.S. Food and Drug Administration (FDA) accepted a supplemental new drug application of ibrutinib for patients with chronic graft-versus-host disease (cGVHD) who have...
Long-Term Study Highlights Limitations of Current TTP Diagnostic Methods
For the past two decades, ADAMTS13 activity has been the backbone of diagnosis for thrombotic thrombocytopenic purpura (TTP); however, a long-term registry study published...
FDA Approves Midostaurin Combination for AML and Systemic Mastocytosis
The U.S. Food and Drug Administration (FDA) approved midostaurin in combination with 7+3 induction and consolidation chemotherapy with daunorubicin and cytarabine for the treatment...
